A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

NCT05924256 | Active Not Recruiting Phase 2

• 1 other identifier: SGC-IIT-umbrella
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.

Conditions

Advanced Salivary Gland Carcinoma

Outcome Measures

Primary Outcomes (1)

• ORR

  Objective response rate defined as the patients confirmed complete response or partial response under RECIST 1.0 criteria.

  at the end of every 2 cycles(for arm1, arm3 and arm4, each cycle is 21 days, for arm2, each cycle is 28 days)

Secondary Outcomes (4)

• DCR

  at the end of every 2 cycles(for arm1, arm3 and arm4, each cycle is 21 days, for arm2, each cycle is 28 days)

• Progression-free Survival (PFS)

  up to 2 years

• Overall Survival (OS)

  up to 2 years

• Adverse events

  Since the signing of informed consent forms to 30 days after the last cycle

Study Arms (4)

Arm 1

EXPERIMENTAL

This arm for HER2-positive salivray gland carcinoma.

Drug: SHR-A1811

Arm 2

EXPERIMENTAL

This arm for AR-postive salivray gland carcinoma.

Drug: SHR 3680 + leuprolide

Arm 3： 3a adenoid cystic carcinoma and 3b non-adenoid cystic carcinoma

EXPERIMENTAL

This arm for salivray gland carcinoma without HER-2 alteration or AR-postive.

Drug: SHR-A1921

Arm 4

EXPERIMENTAL

This arm for low HER2 expression salivray gland carcinoma.

Drug: SHR-A1811

Interventions

SHR-A1811 DRUG

SHR-A1811

Arm 1

SHR 3680 + leuprolide DRUG

SHR 3680 + leuprolide

Arm 2

SHR-A1921 DRUG

SHR-A1921

Arm 3： 3a adenoid cystic carcinoma and 3b non-adenoid cystic carcinoma

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients volunteered to participate in this study and signed informed consent;
• Aged ≥ 18 but ≤ 75 years, male or female;
• Histologically confirmed to be locally advanced or metastatic salivary gland carcinoma;
• Arm1: salivary gland carcinoma patients with HER-2 overexpression ； Arm 2: salivary gland carcinoma patients with AR-positive; Arm 3: salivary gland carcinoma patients without HER-2 alteration or AR-positive; Arm 4: salivary gland carcinoma patients with low HER-2 expression;
• At least one measurable lesion (according to RECIST v1.1, long diameter of measurable lesion scanned by spiral CT should be ≥ 10 mm or short diameter of swollen lymph node should be ≥ 15 mm; according to RECIST vl.1 standards, a previously treated lesion with local treatment can be used as target lesions after clear progress);
• ECOG Perfomance Status: 0\~1;
• Estimated survival time ≥ 12 weeks;
• The main organs function are normal, and meet the following requirements (within 7 days before the start of study treatment):
• Blood routine examination(no blood transfusion within 14 days before screening, no granulocyte colony stimulating factor (G-CSF), no medication corrected):1) Hemoglobin (HB)≥ 90g / L;2) Neutrophil count (ANC) ≥ 1.5 × 109 / L;3) platelets (PLT) ≥ 80 × 109 / L; Blood biochemical tests are subject to the following criteria (no albumin is delivered 14 days prior to screening):1) Serum total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); 2) alanine aminotransferase (ALT), aspartate aminotransferase (AST\])\< 2.5 × ULN; if liver metastasis, ALT and AST ≤ 5 × ULN;3) Serum creatinine (Cr) ≤ 1 × ULN or endogenous creatinine clearance \> 50ml / min (Cockcroft-Gault formula); International normalized ratio (INR) ≤ 2.3 or prothrombin time (PT) exceeds the range of normal controls ≤ 6 seconds; Urine protein \<2+ (if urine protein ≥ 2+, 24-hour urine protein can be quantified, 24-hour urine protein quantitation \<1.0g can be included);
• Women of childbearing age must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and volunteer to use appropriate methods during the observation period and within 8 weeks after the last study drug administration; for men, sterilization surgery should be performed, or agree to use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug;
• Patient who are expected to have good compliance and can accept follow-up visit for the efficacy and adverse reactions according to the program requirements.

You may not qualify if:

• Have other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast carcinoma in situ, can be enrolled.
• Other anti-tumor treatments (including but not limited to chemotherapy, radiotherapy, etc.) were used within 28 days prior to the first use of the study drug. if the last dose of anti-tumor drug had been stopped ≥ 5 half-life can be allowed.
• There are clinical symptoms or diseases of the heart that are not well controlled, such as:
• According to the New York Heart Association (NYHA) standard, level II or higher cardiac dysfunction or echocardiography: left ventricular ejection fraction\<50%; unstable angina; Myocardial infarction occurred within 1 year before the start of treatment; Clinically significant supraventricular or ventricular arrhythmia that requires treatment or intervention; corrected QT interval(QTc) \> 450ms (male); QTc \> 470ms (female) (Calculation of QTc interval with Fridericia formula; if the QTc is abnormal, it can be detected three times at an interval of 2 minutes, and the average value is taken);
• Patients with high blood pressure who cannot be reduced to normal range by antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg) (average of BP based on ≥2 measurements), allowing the use of antihypertensive treatment to achieve the above parameters.
• A variety of factors that affect the absorption of oral medications (such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction) (Only apply for Arm 2 patients);
• Patients with a risk of gastrointestinal bleeding may not be enrolled, including the following: (1) active digestive ulcer lesions, and fecal occult blood (++); (2) those with a history of melena and hematemesis within 3 months;
• Abnormal coagulation function (INR\>1.5×ULN,activated partial thromboplastin time\>1.5×ULN), with bleeding tendency.

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Dongmei Ji

Shanghai, China

Location

MeSH Terms

Interventions

Leuprolide

Intervention Hierarchy (Ancestors)

Gonadotropin-Releasing Hormone; Pituitary Hormone-Releasing Hormones; Hypothalamic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins

Study Officials

• Dongmei Ji, Doctor

  Fudan University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: June 21, 2023
• First Posted: June 29, 2023
• Study Start: July 26, 2023
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: April 2, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)